Tevogen Bio to Host AI and Healthcare Economics Panels at J.P. Morgan Healthcare Conference

Tevogen Bio Announces AI and Healthcare Panels at J.P. Morgan Conference

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) is set to host two significant panel discussions at the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on January 13, 2025 1

1

2

2

3

3

4

4

. The event, known as the largest and most informative healthcare investment symposium in the industry, will feature discussions on artificial intelligence in biopharma and the economics of healthcare.

AI in Biopharma: Next Frontier of Medical Innovation

The first panel, scheduled from 2:00 PM to 2:30 PM PST, will focus on the role of AI in the biopharmaceutical industry 1

1

4

4

. This discussion aims to highlight how AI-driven technologies can revolutionize various aspects of the healthcare sector, including:

• Accelerating drug discovery processes
• Enhancing patient accessibility
• Fostering quicker innovation
• Significantly reducing operating costs

The panel will feature notable speakers such as Dr. David Rhew, Global Chief Medical Officer and VP of Healthcare at Microsoft (Nasdaq: MSFT), Dr. Sean Tunis from Rubix Health, and Mittul Mehta, Chief Information Officer and Head of Tevogen.AI at Tevogen Bio 1

1

4

4

.

Pioneering the Economics of Health: Balancing Access and Outcomes

Following a coffee break, a second panel from 3:15 PM to 4:00 PM PST will delve into the economics of healthcare 1

1

3

3

4

4

. This discussion aims to examine the often-overlooked interdependencies within the healthcare ecosystem, moving beyond singular silos to consider the broader economic landscape.

Panelists for this session include:

• Victor Sordillo, MD of Risk Advisory Services at Verita CSG, Inc. and Tevogen Bio Board Member
• Peter Ehrhardt, Senior Partner at Simon-Kucher & Partners
• Dr. Poonam Alaigh, Former Acting Under Secretary for Health, U.S. Department of Veterans Affairs
• Dr. Sean Tunis, Principal at Rubix Health and Senior Fellow at Tufts Center for Evaluation of Value and Risk in Health
• Dr. Ryan Saadi, Founder and CEO of Tevogen Bio 1

  1

  3

  3

  4

  4

Tevogen Bio's Innovative Approach

Tevogen Bio, the host of these panels, is a clinical-stage specialty immunotherapy company focusing on developing off-the-shelf, genetically unmodified precision T cell therapies 1

1

2

2

3

3

4

4

. The company's approach targets infectious diseases, cancers, and neurological disorders, aiming to address significant unmet needs in large patient populations.

Tevogen's leadership emphasizes the importance of patient accessibility through advanced science and innovative business models. The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including patents related to artificial intelligence 1

1

2

2

3

3

4

4

.

Event Details and Significance

The panel discussions will take place at the Marines' Memorial Club & Hotel in San Francisco, with a reception and cocktails following from 4:00 PM to 6:00 PM 4

4

. This event represents a significant opportunity for industry leaders, emerging companies, and investors to engage in discussions about the future of healthcare, particularly in the realms of AI application and economic sustainability.

As the healthcare industry continues to evolve, events like these play a crucial role in shaping the future of medical innovation and accessibility. The convergence of AI technology and healthcare economics at this conference underscores the growing importance of interdisciplinary approaches in addressing complex healthcare challenges.